Dyslipidemia Management in Adults with Diabetes

Diabetes Care

Volumn 27, Issue SUPPL. 1, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BILE ACID BINDING RESIN; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; RESIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; SCREENING; SMOKING CESSATION; WEIGHT REDUCTION;

EID: 1042291190     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.2007.s68     Document Type: Review

References (10)

1. Haffner SM: Management of dyslipidemia in adults with diabetes (Technical Review). Diabetes Care 21:160-178, 1998
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). BMJ 316:823-828, 1998
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016, 2003
4. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
5. American Diabetes Association: Nutrition principles and recommendations in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S36-S46, 2004
6. American Diabetes Association: Physical activity/exercise and diabetes (Position Statement). Diabetes Care 27:S58-S62, 2004
7. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith SC, Washington R: When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association task force on risk reduction. Circulation 95:1683-1685, 1997
8. NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111). JAMA 285: 2486-2497, 2001
9. American Diabetes Association: Detection and management of lipid disorders in diabetes (Consensus Statement). Diabetes Care 16:828-834, 1993
10. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998